<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01036139</url>
  </required_header>
  <id_info>
    <org_study_id>P06-10 / BF 2.649</org_study_id>
    <secondary_id>Eudract number</secondary_id>
    <nct_id>NCT01036139</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease</brief_title>
  <acronym>HARPS1</acronym>
  <official_title>A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioprojet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of BF2.649 over placebo (12 week Double-Blind Phase) and assess the
      long term safety and the efficacy maintenance(9 months Open-Label Extension Phase) of BF2.649
      in the improvement of excessive daytime sleepiness in patients diagnosed with Parkinson's
      Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As measured by the change from baseline in the Epworth Scale Scores (ESS) at Week 12 and at
      Week 51, in patients diagnosed with EDS in Parkinson's Disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ESS change (Epworth Sleepiness Scale)</measure>
    <time_frame>at week 12 / 52 versus baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12-week and 52-week</time_frame>
    <description>Any AE observed and reported during the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">268</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>BF2.649 (pitolisant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BF2.649 (5mg, 10 mg, 20 mg) in capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF2.649 (pitolisant)</intervention_name>
    <description>1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D</description>
    <arm_group_label>BF2.649 (pitolisant)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Pitolisant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a documented history of Parkinson's disease according to
             UPDRS,fluctuating and non-fluctuating patients, Hoehn and Yahr score &lt;5;

          -  stabilized on optimal antiparkinsonian treatments unmodified for 4 weeks prior to
             study entry;

          -  presenting an Excessive Daytime Sleepiness as indicated by an ESS&gt;or=12

        Exclusion Criteria:

          -  Patients with a known diagnosis of other degenerative parkinsonian syndromes (e.g.
             Progressive supra-nuclear palsy, multisystemic atrophy, corticobasal degenerescence,
             diffuse Lewy's Body dementia)

          -  Patients who have shift work, chronic or occasional sleep deprivation, circadian
             rhythm disorders

          -  Patients with a severe depression indicated by (BDI&gt;= 16)or at suicidal risk (BDI item
             G&gt;0) or depression treated for less than 8 weeks

          -  Patients with a cognitive impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kati Gutierrez, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Bioprojet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pr Arnulf</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EDS in Parkinson's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

